Personalized mRNA pancreatic cancer vaccine demonstrates long-term survival in early trial

A personalized mRNA pancreatic cancer vaccine shows lasting efficacy in an early trial. Nearly all patients who responded to the experimental vaccine are still alive six years later, demonstrating a significant survival benefit. The trial, involving 16 patients with early-stage disease, suggests immunotherapy can be effective against pancreatic cancer, a notoriously difficult disease to treat.